Vir Biotechnology (VIR) Net Margin (2018 - 2026)
Vir Biotechnology (VIR) reported Net Margin of 433431.03% for Q1 2026, down 42944142.0% on a YoY basis from N/an in Q1 2025, and down 646870.77% sequentially from 66.99% in Q4 2025.
Vir Biotechnology (VIR) Net Margin (2018 - 2026) Analysis & Trends
Vir Biotechnology (VIR) has 9 years of Net Margin data on file, last reported at 433431.03% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 42944142.0% year-over-year to 433431.03%; the trailing twelve-month figure through Mar 2026 stood at 675.36% (up 209368.0% YoY), and the FY2025 full-year result was 638.87%, up 6453.0% from the prior year.
- Net Margin slipped to 433431.03% in Q1 2026, from 66.99% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 46.81% in Q3 2022 to a low of 433431.03% in Q1 2026.
- A 5-year average of 31858.58% and a median of 845.23% in 2024 frame the typical range for Net Margin.
- Across the five-year window, Net Margin jumped 859021 bps in 2022 and sank 42944142 bps in 2026, its largest moves.
- Tracing VIR's Net Margin over 5 years: stood at 205.63% in 2022, then sank by 236 bps to 690.85% in 2023, then dropped by 22 bps to 845.23% in 2024, then soared by 92 bps to 66.99% in 2025, then plunged by 646871 bps to 433431.03% in 2026.
- Business Quant data shows VIR's Net Margin at 433431.03% in Q1 2026, 66.99% in Q4 2025, and 67975.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vir Biotechnology | 1.38 Bn | 1.38 Bn | - | -433,431.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -433,431.03% |
| Dec 31, 2025 | -66.99% |
| Sep 30, 2025 | -67,975.42% |
| Jun 30, 2025 | -9,139.87% |
| Mar 31, 2025 | -3,989.61% |
| Dec 31, 2024 | -845.23% |
| Sep 30, 2024 | -8,979.71% |
| Jun 30, 2024 | -4,500.10% |
| Mar 31, 2024 | -126.26% |
| Dec 31, 2023 | -690.85% |
| Sep 30, 2023 | -6,192.23% |
| Jun 30, 2023 | -5,129.71% |
| Mar 31, 2023 | -223.80% |
| Dec 31, 2022 | -205.63% |
| Sep 30, 2022 | 46.81% |
| Jun 30, 2022 | -188.27% |
| Mar 31, 2022 | 42.08% |
| Dec 31, 2021 | 64.63% |
| Sep 30, 2021 | 106.57% |
| Jun 30, 2021 | 36.73% |